undamentalytics Newsletter
Sign in

Nuvation Bio Inc. (NUVB) stock

Add to watchlist

Add holding +

NYSE: NUVB NYSE Biotechnology Next results ~November 4, 2026

C Fundamentals grade

Nuvation Bio Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: free cash flow after stock pay is not positive.

Price vs value

Under review: free cash flow after stock pay is not positive. We'll show the comparison once resolved.

Nuvation Bio Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 6 selling1 purchase and 16 sales by directors and officers, last 12 monthsInsider trades
  • Funds147 adding, 76 cuttingOf 48 active managers that changed their stake, 30 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Nuvation Bio files

Where Nuvation Bio stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $170m, up 1083.6% on a year earlier, slower than the 1205.5% growth a quarter earlier. That growth ranks 7 of 122 among the biotechnology companies we cover. Free-cash-flow margin rose to -72.2% from -1179.0% a year earlier. Operating margin widened to -81.0% from -1564.9%. The diluted share count is up 9.5% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades C. It passes 3 of our 6 financial-health checks.

Our model value for Nuvation Bio is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 6, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 4, 2026 (estimated)

Nuvation Bio Inc.'s trailing-twelve-month revenue grew 1083.6% year on year, with a free-cash-flow margin of -72.2%. Where it stands out: revenue growth of 1083.6% ranks 9 of 172 biotechnology companies we cover. Where it lags: change in growth rate of -122.0pp ranks 158 of 172 biotechnology companies we cover.

Current signal Revenue growth decelerating: TTM revenue growth slowed to 1083.6% (-122.0pp vs the prior quarter).

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 1083.6% over the last 12 months, against a median of 12.6% for biotechnology companies we cover.
  • Margins widening. Operating margin is up 1483.9 points on a year ago.

Things to watch

  • Growth slowing. The growth rate is 122.0 points lower than a quarter earlier.
  • Loss-making. Operating margin is -81.0%: costs exceed revenue.
  • Burning cash. Free cash flow was -72.2% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 20.9% of revenue, against a median of 19.2% for biotechnology companies we cover: a real cost that cash-flow figures leave out.
  • Share dilution. Diluted shares rose 9.5% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 82% and a beta of 1.6 against the S&P 500.

Latest results: FY2026 Q2

Filed August 6, 2026
Earnings per share
-$0.15 against an average estimate of -$0.12: missed by 25.1%
Revenue
$32m, up 555.6% on a year earlier
Share reaction
+3.6% in the first session after the results on August 6, 2026, against +0.5% for the S&P 500
Next report
November 4, 2026; average EPS estimate -$0.10

Nuvation Bio's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+1.0%
  • 1 week+1.9%
  • 1 month-9.8%
  • This year-48.8%
  • 1 year-10.3%
  • 5 years-51.2%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$170M
Operating margin
-81.0%
Net margin
-88.2%
EPS (TTM, diluted)
$-0.42

Growth

Revenue growth
+1083.6%
Change in growth rate
−122.0 pts
Share count change
+9.5%

Cash

Free cash flow (TTM)
-$123M
FCF margin
-72.2%
Stock pay % of revenue
20.9%

Earnings

Last results
August 6, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Financing

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Nuvation Bio Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: free cash flow after stock pay is not positive.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Nuvation Bio Inc. as an operating company, with every model that fits that kind of business. Cost of equity 10.8%: the 10-year Treasury yield (4.9%) plus a beta of 1.3 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$0.7 ~$0.6–$0.9 Left out: out of range vs price (0.16x)
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: This model is withheld pending its input or assumption review.
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. ~$0.6 ~$1.3–$4.5 Left out: out of range vs price (0.13x)
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Nuvation Bio Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 202320242025Now
Share price$1.51$2.66$8.96$4.59
Market value$331m$715m$3.1bn$1.6bn
+ Net debt (− = net cash)−$43m−$29m−$111m−$10m
Enterprise value$288m$685m$2.9bn$1.6bn
Multiples
Price / sales —90.8x48.7x9.5x
Price / earnings ————
Price / free cash flow ————
EV / EBITDA ————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 4, 2026, after the close. Analysts expect revenue of $34m and EPS of −$0.10 (range −$0.13 to −$0.09) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.29 +41% $195m +209%
Next −$0.01 +95% $276m +42%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +3.6% on 90 days ago. In the last 30 days, 0 analysts raised Nuvation Bio Inc.'s forecast and 1 cut it.

Consensus EPS forecast Nuvation Bio Inc., last 90 days
−$0.30 −$0.20 −$0.10 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.28 Current fiscal year, 60 days ago: −$0.29 Current fiscal year, 30 days ago: −$0.29 Current fiscal year, 7 days ago: −$0.29 Current fiscal year, Now: −$0.29 −$0.29 Next fiscal year, 90 days ago: −$0.06 Next fiscal year, 60 days ago: −$0.06 Next fiscal year, 30 days ago: −$0.06 Next fiscal year, 7 days ago: −$0.06 Next fiscal year, Now: −$0.01 −$0.01

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.28−$0.06
60 days ago −$0.29−$0.06
30 days ago −$0.29−$0.06
7 days ago −$0.29−$0.06
Now −$0.29−$0.01

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.12 −$0.15 −25.1%
Mar 2026 $0.05 $0.04 −23.6%
Dec 2025 −$0.04 −$0.09 −91.1%
Sept 2025 −$0.15 −$0.14 +7.0%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

13 analysts, Oct 2026
Buy1292%
Hold18%
Sell00%

Monthly trend

  1. Oct 202639113
  2. Sep 202639113
  3. Aug 202638112
  4. Jul 202627110

Counts of recommendations published by analysts covering Nuvation Bio Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
29.6%
of tradable shares
Days to cover
11.57
at average volume
Short interest, 1 month
+9%
to October 15, 2026
Held by institutions
68%
of shares
Held by insiders
17.2%
of shares
Employees
305
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −12.1%

$5.22 on October 31, 2025 to $4.59

ThenNowEffect
Revenue (last 12 months) $14m $170m +1083.6%
P/S multiple 117.3x 9.5x −91.9%
Share count 323m 353m −8.7%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
NUVB−27%−77%−21%+76%+237%−49%
Industry peers (median)−36%−56%−17%−29%−5%−26%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
NUVB42%25%50%50%58%55%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
NUVB−47%−81%−61%−49%−49%−55%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since August 26, 2020: 93% from March 19, 2021 to October 31, 2023. Getting back needed a 1411% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$4.05 – $9.54
From 52-week high
−51.9%
vs 50-day average
−17.8%
vs 200-day average
−14.8%
Volatility (1 year)
82%
Beta vs S&P 500
1.62

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
6 up, 6 down
typical move ±9.5%
After a week
7 up, 5 down
typical move ±14.7%
After a month
7 up, 5 down
typical move ±28.2%
Results releasedNext dayS&P 500 next day5 days21 days
August 6, 2026 +3.6% +0.5% −4.2% +6.9%
May 4, 2026 +7.6% +0.4% +6.0% +5.1%
March 2, 2026 −26.2% −0.8% −20.0% −27.4%
January 12, 2026 −18.5% 0.0% −25.2% −28.9%
November 3, 2025 −7.5% −1.0% −11.1% +60.3%
August 7, 2025 −2.1% +0.7% +17.4% +48.5%
May 7, 2025 +0.5% +1.1% +3.8% +18.7%
March 6, 2025 +8.0% −1.2% +18.2% −11.2%
November 6, 2024 +12.9% +3.3% +27.2% +22.8%
August 5, 2024 −11.3% −2.0% −16.1% −10.4%
May 14, 2024 −2.1% +1.7% +0.9% −11.3%
February 29, 2024 +13.2% +1.3% +26.4% +87.3%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Nuvation Bio Inc. in five measures

Fundamentals grade C
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Nuvation Bio Inc.
$0 $50M $100M $150M $200M FY24 Q1 FY24 Q3 FY25 Q1 FY25 Q3 FY26 Q2 Revenue (TTM), FY24 Q1: $0 Revenue (TTM), FY24 Q2: $1.4M Revenue (TTM), FY24 Q3: $2.2M Revenue (TTM), FY24 Q4: $7.9M Revenue (TTM), FY25 Q1: $11M Revenue (TTM), FY25 Q2: $14.4M Revenue (TTM), FY25 Q3: $26.7M Revenue (TTM), FY25 Q4: $62.9M Revenue (TTM), FY26 Q1: $143M Revenue (TTM), FY26 Q2: $169.9M $169.9M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY24 Q1 $0
FY24 Q2 $1.4M
FY24 Q3 $2.2M
FY24 Q4 $7.9M
FY25 Q1 $11M
FY25 Q2 $14.4M
FY25 Q3 $26.7M
FY25 Q4 $62.9M
FY26 Q1 $143M
FY26 Q2 $169.9M
Revenue growth, TTM YoY Nuvation Bio Inc.
600% 800% 1000% 1200% 1400% FY25 Q2 FY25 Q3 FY25 Q4 FY26 Q1 FY26 Q2 Revenue growth, TTM YoY, FY25 Q2: 900.3% Revenue growth, TTM YoY, FY25 Q3: 1137.2% Revenue growth, TTM YoY, FY25 Q4: 699.0% Revenue growth, TTM YoY, FY26 Q1: 1205.5% Revenue growth, TTM YoY, FY26 Q2: 1083.6% 1083.6%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY25 Q2 900.3%
FY25 Q3 1137.2%
FY25 Q4 699.0%
FY26 Q1 1205.5%
FY26 Q2 1083.6%
Operating margin (TTM) Nuvation Bio Inc.
-40000% -30000% -20000% -10000% 0% FY24 Q2 FY24 Q4 FY25 Q2 FY25 Q4 FY26 Q2 Operating margin (TTM), FY24 Q2: -37474.1% Operating margin (TTM), FY24 Q3: -25879.6% Operating margin (TTM), FY24 Q4: -7527.3% Operating margin (TTM), FY25 Q1: -5762.8% Operating margin (TTM), FY25 Q2: -1564.9% Operating margin (TTM), FY25 Q3: -871.0% Operating margin (TTM), FY25 Q4: -338.7% Operating margin (TTM), FY26 Q1: -105.0% Operating margin (TTM), FY26 Q2: -81.0% -81.0%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY24 Q2 -37474.1%
FY24 Q3 -25879.6%
FY24 Q4 -7527.3%
FY25 Q1 -5762.8%
FY25 Q2 -1564.9%
FY25 Q3 -871.0%
FY25 Q4 -338.7%
FY26 Q1 -105.0%
FY26 Q2 -81.0%
FCF margin (TTM) Nuvation Bio Inc.
-6000% -4000% -2000% 0% FY24 Q2 FY24 Q4 FY25 Q2 FY25 Q4 FY26 Q2 FCF margin (TTM), FY24 Q2: -5897.0% FCF margin (TTM), FY24 Q3: -4609.6% FCF margin (TTM), FY24 Q4: -1665.1% FCF margin (TTM), FY25 Q1: -1444.5% FCF margin (TTM), FY25 Q2: -1179.0% FCF margin (TTM), FY25 Q3: -715.6% FCF margin (TTM), FY25 Q4: -278.5% FCF margin (TTM), FY26 Q1: -89.3% FCF margin (TTM), FY26 Q2: -72.2% -72.2%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY24 Q2 -5897.0%
FY24 Q3 -4609.6%
FY24 Q4 -1665.1%
FY25 Q1 -1444.5%
FY25 Q2 -1179.0%
FY25 Q3 -715.6%
FY25 Q4 -278.5%
FY26 Q1 -89.3%
FY26 Q2 -72.2%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 0 8 63 170
Gross profit 0 1 — —
EBITDA −100 −592 −211 −135
Operating income −100 −593 −213 −138
Net income −76 −568 −205 −150
Diluted EPS −$0.35 −$2.11 −$0.60 −$0.42
Growth (year on year)
Revenue — — +699.0% +>999%
Margins
Gross margin — 10.1% — —
EBITDA margin — <−999% −336.0% −79.7%
Operating margin — <−999% −338.7% −81.0%
Net margin — <−999% −325.3% −88.2%
Free-cash-flow margin — <−999% −288.4% —
Cash flow
Cash from operations −68 −130 −173 −121
Capital spending — 0 8 —
Free cash flow — −130 −181 —
Stock-based pay 20 32 36 36
Free cash flow after stock pay — −163 −217 —
Balance sheet
Cash 43 36 164 259
Total debt 0 6 53 249
Net debt (negative = net cash) −43 −29 −111 −10
Diluted shares 219m 269m 342m 353m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

3 of 6 checks passed · June 30, 2026
What it owns · $745m
Short-term assets $726mLonger-term assets $18m
What it owes, and who funded it · $745m
Short-term liabilities $87mLonger-term liabilities $404mShareholders' equity $254m
  • Short-term assets cover short-term liabilities $726m of assets due within a year against $87m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $726m short-term assets against $404m of longer-dated liabilities.
  • More cash than debt $259m of cash against $249m of debt.
  • Debt below 40% of shareholders' equity Debt is 98% of equity.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt −$121m of operating cash flow against $249m of debt.
  • Operating profit covers interest at least five times over Operating income of −$138m against $27m of interest.

From Nuvation Bio Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+9.5%
year over year
R&D spending
75.8%
of revenue
Sales & admin spending
93.3%
of revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated NUVB IBRX ABUS BEAM URGN KPTI Median
Revenue, last 12 months $170m $166m $182m $156m $189m $147m $56m
Revenue growth, last 12 months >999% 192.9% >999% 158.9% 100.3% 6.8% 12.6%
Revenue growth, 3-year average — 554.3% 97.6% 24.9% 37.6% 0.1% 13.7%
Revenue growth, latest quarter 555.6% 93.9% −90.6% −94.2% 199.2% −11.9% 10.2%
Gross margin 54.3% 99.3% — — 90.8% — 82.9%
Operating margin −81.0% −151.9% 82.0% −242.3% −35.3% −56.2% −189.4%
Operating margin, 3-year average <−999% <−999% −377.3% −344.8% −86.7% −76.7% −363.5%
Net margin −88.2% −598.6% 84.2% −54.7% −51.7% −153.3% −169.8%
Cash from operations / revenue −70.9% −169.6% −13.6% −230.3% −84.2% −44.6% −168.0%
Free-cash-flow margin −72.2% −173.8% −13.6% −238.9% −84.3% −44.6% −162.4%
Free-cash-flow margin, 3-year average <−999% <−999% −376.7% −290.8% −105.5% −69.7% −310.0%
Stock pay / revenue 20.9% 20.7% 3.0% 52.2% 8.5% 7.9% 20.0%
Change in share count 9.5% 26.1% 1.9% 16.3% 4.7% 22.0% 8.2%

Median of all 184 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

184 biotechnology companies
Measure Company Peer median Rank
Revenue growth Growth 1083.6% 12.6% 9 of 172
Change in growth rate Growth -122.0pp -0.1pp 158 of 172
Gross margin Profitability 54.3% 82.4% 66 of 75
Operating margin Profitability -81.0% -189.4% 70 of 175
Net margin Profitability -88.2% -157.3% 79 of 180
Free-cash-flow margin Cash generation -72.2% -145.4% 76 of 176
Stock pay as % of revenue Cash generation 20.9% 19.2% 93 of 179
Long-term debt as % of assets Balance sheet 32.6% 20.6% 57 of 78
Change in share count Balance sheet 9.5% 7.9% 88 of 156

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue YoY
Licenses $38.2M ▲ 385.7%
Product Revenue $24.7M —
Products $24.7M —

These categories overlap or exclude eliminations, so shares aren't shown.

Geography
Region Revenue Share YoY
Japan $28.8M 45.8% ▲ 956.5%
United States $24.7M 39.3% —
China $9.4M 14.9% ▲ 82.6%

From Nuvation Bio Inc.'s 10-K filed March 2, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$1.3B
Institutions reporting
240
Shares held vs prior quarter
▲ 5.7%
Positions opened / closed
38 / 25

Top buyers and sellers, Q2 2026: 147 institutions bought and 76 sold ; the biggest buyer was Blackrock, Inc (+2.5M shares) and the biggest seller Jones Hill Capital LP (−2.4M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
FMR LLC $297M 52.2M 22.4% ▲ 0.5%
Blackrock, Inc. $157M 27.6M 11.9% ▲ 10.1%
Decheng Capital LLC $147M 26.0M 11.1% 0.0%
Vanguard Capital Management LLC $67.7M 11.9M 5.1% ▲ 2.5%
Omega Fund Management, LLC $45.9M 8.1M 3.5% 0.0%
Laurion Capital Management LP $44.4M 7.8M 3.4% 0.0%
State Street Corp $41.9M 7.4M 3.2% ▲ 8.6%
Geode Capital Management, LLC $35.5M 6.2M 2.7% ▲ 6.5%
Duquesne Family Office LLC $25.8M 4.5M 1.9% 0.0%
American Century Companies Inc $25.6M 4.5M 1.9% ▲ 55.3%
Bank Of America Corp $20M 3.5M 1.5% ▲ 9.6%
Tang Capital Management LLC $18.7M 3.3M 1.4% ▲ 4.8%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Nuvation Bio Inc.'s complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $118,250 1 trade by 1 insider, last 12 months Insider sales History → $9.2M 16 trades by 6 insiders · 38% under pre-set plans
Net ▼ $9.1M net selling
Insider Date Trade Shares Price Value
Hattersley Gary CHIEF SCIENTIFIC OFFICER August 19, 2026 Sell pre-set plan 100,000 $7.09 $709,000
Sauvage Philippe Chief Financial Officer June 23, 2026 Sell pre-set plan 47,668 $6.01 $286,485
Wentworth Kerry CHIEF REGULATORY OFFICER June 23, 2026 Sell pre-set plan 63,000 $6.02 $379,260
Markel Stacy CHIEF PEOPLE OFFICER June 23, 2026 Sell pre-set plan 125,000 $6.03 $753,750
Mashal Robert Director June 9, 2026 Buy 25,000 $4.73 $118,250
Liu Dongfang CHIEF MEDICAL OFFICER April 17, 2026 Sell pre-set plan 50,000 $5.02 $251,000
Wentworth Kerry CHIEF REGULATORY OFFICER April 17, 2026 Sell pre-set plan 36,750 $5.01 $184,118
Wentworth Kerry CHIEF REGULATORY OFFICER April 6, 2026 Sell pre-set plan 200,000 $4.52 $904,000
Liu Dongfang CHIEF MEDICAL OFFICER December 1, 2025 Sell 150,000 $7.82 $1.2M
Liu Dongfang CHIEF MEDICAL OFFICER November 26, 2025 Sell 10,000 $8.00 $80,000
Liu Dongfang CHIEF MEDICAL OFFICER November 25, 2025 Sell 10,000 $7.50 $75,000
Liu Dongfang CHIEF MEDICAL OFFICER November 20, 2025 Sell 20,000 $7.00 $140,000

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around October 26, 2026 estimated from the company's past filing pattern, not announced

  • August 6, 2026
  • May 4, 2026
  • March 2, 2026
  • January 12, 2026
  • November 3, 2025
  • August 7, 2025

Recent SEC filings

Data status

When each part of this page on Nuvation Bio Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Nuvation Bio Inc. in brief

What does Nuvation Bio Inc. do?
Nuvation Bio Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Nuvation Bio Inc.'s stock ticker?
Nuvation Bio Inc. trades under the ticker NUVB on NYSE. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Nuvation Bio Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Nuvation Bio Inc. reported revenue of $170M, 1083.6% higher than a year earlier, according to its SEC filings.
What is Nuvation Bio Inc.'s free cash flow?
Nuvation Bio Inc.'s free-cash-flow margin is -72.2% of revenue over the trailing twelve months, ranking 76 of the 176 biotechnology companies we cover.
Who are Nuvation Bio Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are FMR LLC, Blackrock, Inc. and Decheng Capital LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Nuvation Bio Inc.'s market cap?
On November 2, 2026, Nuvation Bio Inc.'s market capitalisation was about $1.6B and net debt of -$10.1M. Market figures come from third-party market data and may be delayed.
How much debt does Nuvation Bio Inc. have?
Nuvation Bio Inc.'s debt-to-equity ratio is 97.9%, from its latest balance sheet. The financial health section below sets out its other solvency checks.
Who are Nuvation Bio Inc.'s competitors?
In our Biotechnology peer group, the companies closest to Nuvation Bio Inc. are Immunitybio, Inc., Arbutus Biopharma Corp, Beam Therapeutics Inc., Urogen Pharma Ltd. and Karyopharm Therapeutics Inc. The side-by-side comparison below sets their revenue, margins and growth against Nuvation Bio Inc.'s.
Are insiders buying or selling Nuvation Bio Inc. stock?
Over the last 12 months, Nuvation Bio Inc.'s directors and officers reported 1 open-market purchases and 16 sales on Form 4. The insider trading page charts every trade.
When is Nuvation Bio Inc.'s next earnings date?
Around November 4, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Nuvation Bio Inc. announces its own schedule.